SavedAdd your journal

Journals / Güncel Retina Dergisi / 2018 / Cilt: 2 - Sayı: 1

Anti-VEGF Treatment for Retinopathy of Prematurity

Prematüre Retinopatisinde Anti-VEGF Tedavisi

Hüseyin YETİK
Pages
43–47
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Besides its strikingly successful results debate depending upon positive and negative predictions in the literature with bothering medicolegal issues explains the need for such a review article aiming to clarify the current status and actual practice about anti-VEGF treatment for retinopathy of prematurity

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nowadays anti-VEGF treatment for ROP is increasingly gaining popularity on the way to replace laser as monotherapy.
📊
Key Findings & Data:Nowadays anti-VEGF treatment for ROP is increasingly gaining popularity on the way to replace laser as monotherapy.
💡
Conclusion & Impact:Besides its strikingly successful results debate depending upon positive and negative predictions in the literature with bothering medicolegal issues explains the need for such a review article aiming to clarify the current status and actual practice about anti-VEGF treatment for retinopathy of prematurity
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Nowadays anti-VEGF treatment for ROP is increasingly gaining popularity on the way to replace laser as monotherapy. Besides its strikingly successful results debate depending upon positive and negative predictions in the literature with bothering medicolegal issues explains the need for such a review article aiming to clarify the current status and actual practice about anti-VEGF treatment for retinopathy of prematurity

Özet

Prematüre retinopatisinde anti-VEGF kullanımı giderek artmakta ve lazer tedavisinin yerini alarak monoterapi seçeneği olarak karşımıza çıkmaktadır. Tedavinin çarpıcı olumlu sonuçları yanında literatürde olumlu olumsuz görüşlerin ortaya çıkardığı kafa karışıklığı ek medikolegal konularla daha da artmaktadır. Bu yazı bu tedavinin güncel durumu ve pratiğine ilişkin pek çok soru işaretine açıklık getirmeye dönük bir derleme yazısıdır

🔖

Cite This Article

YETİK, H. (2018). Anti-VEGF Treatment for Retinopathy of Prematurity. Güncel Retina Dergisi, Cilt: 2 - Sayı: 1, 43–47. https://ajindex.com/articles/224249

References (17)

  1. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res. 2004
  2. 32 2- Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007
  3. 245(11): 1727-30. 3- Drenser KA. Anti-angiogenic therapy in the management of retinopathy of prematurity. Dev Ophthalmol. 2009
  4. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr. 2009
  5. 21(2):182-7. 5- Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina. 2008
  6. 28(3 Suppl): S19-25. 6- Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina. 2008
  7. 28(3 Suppl): S13-8. 7- Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008
  8. 92(11): 1450-5. 8- Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol. 2009
  9. 148(4): 536-543.e2. 9- Mintz-Hittner HA, Kennedy KA, Chuang AZ
  10. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011
  11. 364(7):603-15. 10- Fierson WM
  12. American Academy of Pediatrics Section on Ophthalmology
  13. American Academy of Ophthalmology
  14. American Association for Pediatric Ophthalmology and Strabismus
  15. American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013
  16. 131(1):189-95. 11- Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2015
  17. 253(10):1677-83. 12- Yetik H. Limited laser treatment covering the demarcation line in retinopathy of prematurity - A new hypothesis in the pathogenesis of ROP. Session: Vascular Diseases and Diabetic Retinopathy. Euretina Conference. Paris 2010. Abstract Book 13- Yetik H. Limited laser treatment for retinopathy of prematurity: A new hypoth